US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

BDRX Biodexa Pharmaceuticals PLC

1.01

0.01 (1.00%)

Última actualización: 08:33:36

Retrasado por 15 minutos

Biotech Shares Bid Up Premarket Following 9.9% Institutional Stake Disclosure

With biotech stocks finding trememdous success in recent months, it’s no wonder why everyone wants to get in on the action, including institutional investors. After...

To read the full story on AllPennyStocks.com, click here.

Biodexa Pharmaceuticals (NASDAQ:BDRX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas Biodexa Pharmaceuticals.

Biodexa Pharmaceuticals (NASDAQ:BDRX)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas Biodexa Pharmaceuticals.

Noticias sobre Biodexa Pharmaceuticals PLC BDRX

Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
Martes 30 de Abril 2024 (1 semana hace) • GlobeNewswire Inc.

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
Viernes 26 de Abril 2024 (2 semanas hace) • GlobeNewswire Inc.

Preliminary Results for the Year Ended 31 December 2023
Viernes 19 de Abril 2024 (3 semanas hace) • GlobeNewswire Inc.

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
Viernes 23 de Febrero 2024 (2 meses hace) • GlobeNewswire Inc.

Biotech Shares Bid Up Premarket Following 9.9% Institutional Stake Disclosure
Martes 13 de Febrero 2024 (3 meses hace) • AllPennyStocks.com

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
Jueves 8 de Febrero 2024 (3 meses hace) • GlobeNewswire Inc.

Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
Miércoles 7 de Febrero 2024 (3 meses hace) • GlobeNewswire Inc.

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
Lunes 22 de Enero 2024 (4 meses hace) • GlobeNewswire Inc.

Biodexa Appoints Ann Merchant to the Board of Directors
Viernes 29 de Diciembre 2023 (4 meses hace) • GlobeNewswire Inc.

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
Jueves 21 de Diciembre 2023 (5 meses hace) • GlobeNewswire Inc.

Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
Martes 19 de Diciembre 2023 (5 meses hace) • GlobeNewswire Inc.

Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
Lunes 27 de Noviembre 2023 (5 meses hace) • GlobeNewswire Inc.

Más de Biodexa Pharmaceuticals PLC Artículos de Noticias

BNP Paribas (QX)

Deutsche Telekom (QX)

Health Care Select Sector

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones